REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
March 21, 2024 at 04:40 am EDT
Share
REYON Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported negative sales was KRW 0.00009 million compared to sales of KRW 0.00026 million a year ago. Net income was KRW 3,583.37 million compared to KRW 7,433.68 million a year ago.
Basic earnings per share from continuing operations was KRW 195 compared to KRW 415 a year ago. Basic earnings per share was KRW 195 compared to KRW 415 a year ago.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
